Skip to main content
. 2022 Nov 3;60(5):2102467. doi: 10.1183/13993003.02467-2021

FIGURE 2.

FIGURE 2

Flow diagram of study participants included in this study. Patients from two 3-year observation periods before and after the first Drug Safety Communication by the US Food and Drug Administration in 2008 were chosen. NHIS: National Health Insurance Service; AR: allergic rhinitis; LTRA: leukotriene receptor antagonist; NPE: neuropsychiatric event.